Golodirsen clinical trials
Also written SRP-4053 and VYONDYS 53.
How each study uses golodirsen is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 12 Dec 2019 · VYONDYS 53 · NDA 211970 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 2
Sarepta Therapeutics, Inc. (3) · Kevin Flanigan (1) · Rare Disease Research, LLC (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses golodirsen is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- An Open-Label Study of Golodirsen in Non-Ambulant Patients With Duchenne Muscular DystrophyTerminatedPhase 4Rare Disease Research, LLCNCT04708314Written as Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53]How we know
- Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)CompletedPhase 3Sarepta Therapeutics, Inc.NCT02500381Written as SRP-4053How we know
- An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular DystrophyTerminatedPhase 3Sarepta Therapeutics, Inc.NCT03532542Written as GolodirsenHow we know
- A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.CompletedPhase 2Kevin FlaniganNCT04179409Written as Vyondys 53How we know
- Phase I/II Study of SRP-4053 in DMD PatientsCompletedPhase 1/2Sarepta Therapeutics, Inc.NCT02310906Written as SRP-4053How we know
Codes
What other systems call golodirsen · ClinicalTrials.gg INT001424
- MeSH (NLM) C000710673golodirsenConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 033072U4MZGOLODIRSENConfirmed FDA, NLM
- RxNorm 2267207One source FDA
- NCI Thesaurus C175077GolodirsenOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000710673 | golodirsen | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 033072U4MZ | GOLODIRSEN | Confirmed FDA, NLM |
| RxNorm | 2267207 | — | One source FDA |
| NCI Thesaurus | C175077 | Golodirsen | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.